BMC Biotechnology · 2015 · 11 citations · 25 references
Life SciencesBiochemistryBiotechnologyInnate ImmunityMolecular BiotechnologyProtein EngineeringChromatographic PurificationProduct PurificationProtein Expression EngineeringProtein PurificationCell LysisEscherichia ColiEscherichia Coli Expression SystemsHelicobacter Pylori InfectionImmunomodulatory EffectsPurificationPurification Process DevelopmentReactive Oxygen Species Generation
BACKGROUND: Helicobacter pylori neutrophil-activating protein (HP-NAP) is involved in H. pylori-induced gastric inflammation. Due to its immunogenic and immunomodulatory properties, HP-NAP has been used for developing vaccines against H. pylori infection and new drugs for cancer therapy. RESULTS: Here, we provide a simple process for high-yield production of HP-NAP by applying one-step negative chromatography to purify recombinant HP-NAP expressed in Escherichia coli (E. coli). In our E. coli expression system, recombinant HP-NAP constitutes nearly 70% of the total protein. Overexpressed recombinant HP-NAP is almost completely soluble upon cell lysis at pH 9.5. Under the optimal condition at pH 8.0, recombinant HP-NAP with purity higher than 95% can be obtained from E. coli by collecting the unbound fraction using diethylaminoethyl (DEAE) Sephadex resin in batch mode. The overall yield of HP-NAP from a 50-ml E. coli culture is ~19 mg. The purified HP-NAP folds into a multimer with a secondary structure of α-helix and is able to trigger the production of reactive oxygen species by neutrophils. CONCLUSIONS: Purification of recombinant HP-NAP overexpressed in E. coli using DEAE Sephadex negative mode batch chromatography is an efficient method for high-yield production of highly pure HP-NAP in its native state. The purified HP-NAP is useful for various clinical applications including vaccine development, diagnosis, and new drug development.
25
THE PREVALENCE OF HELICOBACTER PYLORI IN PEPTIC ULCER DISEASE
R E Pounder, Dennis Ng · 1995 · 353 citations
Characterization of a Helicobacter pylori neutrophil-activating protein
David J. Evans, D. Gareth Evans, T Takemura et al. · Infection and Immunity · 1995 · 315 citations · Full text
Barbara Satin, Giuseppe Del Giudice, Vittorina Della Bianca et al. · The Journal of Experimental Medicine · 2000 · 309 citations · Full text
The prevalence of Helicobacter pylori in peptic ulcer disease.
Ernst J. Kuipers · PubMed · 1995 · 248 citations